Details of the Drug Combination

General Information of Drug Combination (ID: DC9FO58)

Drug Combination Name

Vismodegib TEM

Indication

Disease Entry	Status	REF
Invasive ductal carcinoma	Investigative	[1]

Component Drugs

Vismodegib DM5IXKQ

TEM DMLNFWU

Small molecular drug

2D MOL

3D MOL

High-throughput Screening Result

Testing Cell Line: T-47D

Zero Interaction Potency (ZIP) Score: 0.84

Bliss Independence Score: 7.69

Loewe Additivity Score: 6.14

LHighest Single Agent (HSA) Score: 7.06

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)

Indication(s) of Vismodegib

Disease Entry	ICD 11	Status	REF
Basal cell carcinoma	2C32	Approved	[2]
Primitive neuroectodermal tumour medulloblastoma	2A00.11	Phase 2	[3]

Vismodegib Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Smoothened homolog (SMO)	TT8J1S3	SMO_HUMAN	Modulator	[5]
------------------------------------------------------------------------------------

Vismodegib Interacts with 2 DME Molecule(s)

DME Name	DME ID	UniProt ID	Mode of Action	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Metabolism	[6]
Cytochrome P450 2C9 (CYP2C9)	DE5IED8	CP2C9_HUMAN	Metabolism	[6]
------------------------------------------------------------------------------------

Vismodegib Interacts with 13 DOT Molecule(s)

DOT Name	DOT ID	UniProt ID	Mode of Action	REF
Tumor necrosis factor receptor superfamily member 10A (TNFRSF10A)	OTBPCU2O	TR10A_HUMAN	Increases Expression	[7]
Tumor necrosis factor receptor superfamily member 10B (TNFRSF10B)	OTA1CPBV	TR10B_HUMAN	Increases Expression	[7]
Zinc finger protein GLI1 (GLI1)	OT1BTAJO	GLI1_HUMAN	Decreases Expression	[7]
Zinc finger protein GLI2 (GLI2)	OTIRV97L	GLI2_HUMAN	Decreases Expression	[7]
Apoptosis regulator Bcl-2 (BCL2)	OT9DVHC0	BCL2_HUMAN	Decreases Expression	[7]
Platelet-derived growth factor receptor alpha (PDGFRA)	OTDJXUCN	PGFRA_HUMAN	Decreases Expression	[7]
Tumor necrosis factor receptor superfamily member 6 (FAS)	OTP9XG86	TNR6_HUMAN	Increases Expression	[7]
Caspase-3 (CASP3)	OTIJRBE7	CASP3_HUMAN	Increases Cleavage	[7]
Protein patched homolog 1 (PTCH1)	OTMG07H5	PTC1_HUMAN	Decreases Expression	[7]
Protein smoothened (SMO)	OTXXE208	SMO_HUMAN	Decreases Expression	[7]
Protein patched homolog 2 (PTCH2)	OTOQ0K9V	PTC2_HUMAN	Decreases Expression	[7]
Suppressor of fused homolog (SUFU)	OT0IRYG1	SUFU_HUMAN	Decreases Response To Substance	[8]
N-myc proto-oncogene protein (MYCN)	OTWD33K1	MYCN_HUMAN	Decreases Response To Substance	[8]
------------------------------------------------------------------------------------


⏷ Show the Full List of 13 DOT(s)

Indication(s) of TEM

Disease Entry	ICD 11	Status	REF
Postherpetic neuralgia	1E91.5	Phase 2	[4]

Test Results of This Drug Combination in Other Disease Systems

Indication	DrugCom ID	Cell Line	Status	REF
Invasive ductal carcinoma	DCSP5KR	BT-549	Investigative	[1]
Adenocarcinoma	DCLIBKC	HT29	Investigative	[9]
Adult acute myeloid leukemia	DCZXHUL	HL-60(TB)	Investigative	[9]
Amelanotic melanoma	DCU3ORN	M14	Investigative	[9]
Amelanotic melanoma	DC8MFP0	MDA-MB-435	Investigative	[9]
Anaplastic large cell lymphoma	DCRYLTX	SR	Investigative	[9]
Astrocytoma	DC5G399	SNB-19	Investigative	[9]
Childhood T acute lymphoblastic leukemia	DCP4JCI	CCRF-CEM	Investigative	[9]
Chronic myelogenous leukemia	DCY13ST	K-562	Investigative	[9]
Cutaneous melanoma	DCFHMZB	SK-MEL-5	Investigative	[9]
Glioma	DC56XXU	SF-268	Investigative	[9]
High grade ovarian serous adenocarcinoma	DCDHEJZ	OVCAR-8	Investigative	[9]
Lung adenocarcinoma	DCH1L8R	HOP-62	Investigative	[9]
Lung adenocarcinoma	DCTSSHO	MDA-MB-231	Investigative	[9]
Malignant melanoma	DCR1CDH	LOX IMVI	Investigative	[9]
Malignant melanoma	DC4398N	UACC62	Investigative	[9]
Melanoma	DC8OCUF	UACC-257	Investigative	[9]
Papillary renal cell carcinoma	DC012X8	ACHN	Investigative	[9]
Plasma cell myeloma	DC8IQ00	RPMI-8226	Investigative	[9]
Pleural epithelioid mesothelioma	DCAIRNR	NCI-H226	Investigative	[9]
------------------------------------------------------------------------------------


⏷ Show the Full List of 20 DrugCom(s)

References

1	Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.
2	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6975).
3	A phase II, multicenter, open-label, 3-cohort trial evaluating the efficacy and safety of vismodegib in operable basal cell carcinoma. J Am Acad Dermatol. 2015 Jul;73(1):99-105.e1.
4	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800030055)
5	Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
6	The dawn of hedgehog inhibitors: Vismodegib. J Pharmacol Pharmacother. 2013 Jan;4(1):4-7.
7	Hedgehog signaling antagonist GDC-0449 (Vismodegib) inhibits pancreatic cancer stem cell characteristics: molecular mechanisms. PLoS One. 2011;6(11):e27306. doi: 10.1371/journal.pone.0027306. Epub 2011 Nov 8.
8	Epigenetic targeting of Hedgehog pathway transcriptional output through BET bromodomain inhibition. Nat Med. 2014 Jul;20(7):732-40. doi: 10.1038/nm.3613. Epub 2014 Jun 29.
9	Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.